Pieter L Jager

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9112427/publications.pdf

Version: 2024-02-01

83 papers	5,334 citations	109137 35 h-index	82410 72 g-index
84 all docs	84 docs citations	84 times ranked	4984 citing authors

#	Article	IF	Citations
1	Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer. Clinical Pharmacology and Therapeutics, 2010, 87, 586-592.	2.3	685
2	Indium-111â€“Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2276-2282.	0.8	270
3	[18F]FLT-PET in oncology: current status and opportunities. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1659-1672.	3.3	266
4	Esophageal Cancer: CT, Endoscopic US, and FDG PET for Assessment of Response to Neoadjuvant Therapyâ€”Systematic Review. Radiology, 2005, 236, 841-851.	3.6	264
5	Improved Staging of Patients With Carcinoid and Islet Cell Tumors With ¹⁸F-Dihydroxy-Phenyl-Alanine and ¹¹C-5-Hydroxy-Tryptophan Positron Emission Tomography. Journal of Clinical Oncology, 2008, 26, 1489-1495.	0.8	240
6	Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncology, The, 2006, 7, 728-734.	5.1	234
7	Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. Journal of Nuclear Medicine, 2004, 45, 695-700.	2.8	189
8	6-l-¹⁸F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications. Journal of Nuclear Medicine, 2008, 49, 573-586.	2.8	178
9	6-[F-18]Fluoro-<scp>l</scp>-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3922-3930.	1.8	153
10	Preclinical characterisation of 111 In-DTPA-trastuzumab. British Journal of Pharmacology, 2004, 143, 99-106.	2.7	140
11	Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. Critical Reviews in Oncology/Hematology, 2009, 71, 199-213.	2.0	135
12	Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis. American Journal of Medicine, 2006, 119, 355.e15-355.e24.	0.6	129
13	Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nuclear Medicine Communications, 2004, 25, 433-438.	0.5	118
14	¹⁸F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation. Journal of Nuclear Medicine, 2008, 49, 524-531.	2.8	116
15	¹¹¹In-Octreotide Is Superior to ¹²³I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas. Journal of Nuclear Medicine, 2008, 49, 1232-1237.	2.8	115
16	Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocrine-Related Cancer, 2005, 12, 273-280.	1.6	112
17	The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 958-965.	3.3	107
18	Impact of a new ultrafast CZT SPECT camera for myocardial perfusion imaging: fewer equivocal results and lower radiation dose. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1048-1055.	3.3	86

#	Article	IF	Citations
19	Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. Journal of Gastrointestinal Surgery, 2005, 9, 54-61.	0.9	84
20	Prognostic Value of Coronary Artery Calcium Scoring in Addition to Single-Photon Emission Computed Tomographic Myocardial Perfusion Imaging in Symptomatic Patients. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	84
21	Better Yield of 18Fluorodeoxyglucose-Positron Emission Tomography in Patients with Metastatic Differentiated Thyroid Carcinoma during Thyrotropin Stimulation. Thyroid, 2002, 12, 381-387.	2.4	81
22	Prognostic Value of the Standardized Uptake Value in Esophageal Cancer. American Journal of Roentgenology, 2005, 185, 436-440.	1.0	75
23	18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. Journal of Nuclear Medicine, 2004, 45, 226-31.	2.8	70
24	Imaging Techniques in Nuclear Cardiology for the Assessment of Myocardial Viability. International Journal of Cardiovascular Imaging, 2006, 22, 63-80.	0.7	68
25	The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. European Journal of Endocrinology, 2008, 158, 77-83.	1.9	68
26	Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. European Journal of Endocrinology, 2003, 148, 589-596.	1.9	60
27	Manipulation of [11C]-5-Hydroxytryptophan and 6-[18F]Fluoro-3,4-Dihydroxy-l-Phenylalanine Accumulation in Neuroendocrine Tumor Cells. Cancer Research, 2008, 68, 7183-7190.	0.4	54
28	Vertebral Fracture Assessment in Supine Position: Comparison by Using Conventional Semiquantitative Radiography and Visual Radiography. Radiology, 2009, 251, 822-828.	3.6	54
29	Prediction of functional recovery after revascularization in patients with coronary artery disease and left ventricular dysfunction by gated FDG-PET. Journal of Nuclear Cardiology, 2006, 13, 210-219.	1.4	52
30	Pitfalls of Positive Findings in Staging Esophageal Cancer With F-18-Fluorodeoxyglucose Positron Emission Tomography. Annals of Surgical Oncology, 2003, 10, 1100-1105.	0.7	49
31	Coronary Artery Calcium Scoring to Exclude Flow-Limiting Coronary Artery Disease in Symptomatic Stable Patients at Low or Intermediate Risk. Radiology, 2013, 269, 77-83.	3.6	47
32	Prediction of functional recovery after revascularization in patients with chronic ischaemic left ventricular dysfunction: head-to-head comparison between 99mTc-sestamibi/18F-FDG DISA SPECT and 13N-ammonia/18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 716-723.	3.3	46
33	Diagnostic Performance and Prognostic Value of Extravascular Retention of 123I-Labeled Serum Amyloid P Component in Systemic Amyloidosis. Journal of Nuclear Medicine, 2007, 48, 865-872.	2.8	45
34	Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?. Journal of Nuclear Medicine, 2004, 45, 1677-82.	2.8	45
35	Carbon-11 choline or FDG-PET for staging of oesophageal cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1845-1849.	3.3	44
36	Improving the Detection of Small Lesions Using a State-of-the-Art Time-of-Flight PET/CT System and Small-Voxel Reconstructions. Journal of Nuclear Medicine Technology, 2015, 43, 21-27.	0.4	35

#	Article	IF	Citations
37	Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. Journal of Nuclear Medicine, 2005, 46, 1240-3.	2.8	34
38	Routine bone scintigraphy in primary staging of soft tissue sarcoma. Cancer, 2000, 89, 1726-1731.	2.0	33
39	Myocardial perfusion imaging with a cadmium zinc telluride-based gamma camera versus invasive fractional flow reserve. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 956-962.	3.3	32
40	Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. Arthritis Care and Research, 2010, 62, 296-301.	1.5	30
41	Comparison of 99mTc-sestamibi/18FDG DISA SPECT with PET for the detection of viability in patients with coronary artery disease and left ventricular dysfunction. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 972-979.	3.3	27
42	Prognostic value of normal stress-only myocardial perfusion imaging: a comparison between conventional and CZT-based SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 296-301.	3.3	27
43	Prognostic Value of Myocardial Perfusion Imaging with a Cadmium-Zinc-Telluride SPECT Camera in Patients Suspected of Having Coronary Artery Disease. Journal of Nuclear Medicine, 2017, 58, 1459-1463.	2.8	26
44	Repeated [131I]Metaiodobenzylguanidine Therapy in Two Patients with Malignant Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5888-5895.	1.8	25
45	Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 124-130.	3.3	24
46	Combined Vertebral Fracture Assessment and Bone Mineral Density Measurement: A Patient-friendly New Tool with an Important Impact on the Canadian Risk Fracture Classification. Canadian Association of Radiologists Journal, 2010, 61, 194-200.	1.1	24
47	Effect of attenuation correction on the interpretation of 99mTc-sestamibi myocardial perfusion scintigraphy: the impact of 1 year's experience. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1505-1509.	3.3	23
48	Embolization Therapy of Bone Metastases from Epithelial Thyroid Carcinoma: Effect on Symptoms and Serum Thyroglobulin. Thyroid, 2008, 18, 1277-1284.	2.4	23
49	The influence of coronary calcium score on the interpretation of myocardial perfusion imaging. Journal of Nuclear Cardiology, 2014, 21, 368-374.	1.4	23
50	Technical note: how to determine the FDG activity for tumour PET imaging that satisfies European guidelines. EJNMMI Physics, 2016, 3, 22.	1.3	22
51	Added value of attenuation-corrected Tc-99m tetrofosmin SPECT for the detection of myocardial viability: Comparison with FDG SPECT. Journal of Nuclear Cardiology, 2004, 11, 689-696.	1.4	19
52	Minimizing Patient-Specific Tracer Dose in Myocardial Perfusion Imaging Using CZT SPECT. Journal of Nuclear Medicine Technology, 2015, 43, 36-40.	0.4	19
53	Prevalence, location, and extent of significant coronary artery disease in patients with normal myocardial perfusion imaging. Journal of Nuclear Cardiology, 2014, 21, 284-290.	1.4	18
54	SUV variability in EARL-accredited conventional and digital PET. EJNMMI Research, 2019, 9, 106.	1.1	18

#	Article	IF	Citations
55	Myocardial perfusion quantification in patients suspected of cardiac syndrome X with positive and negative exercise testing: A [13N]ammonia positron emission tomography study. Nuclear Medicine Communications, 2006, 27, 791-794.	0.5	17
56	[18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Oral Oncology, 2009, 45, e211-e215.	0.8	17
57	PET/CT using 18F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. Nuclear Medicine Communications, 2012, 33, 322-330.	0.5	17
58	Development of a radioiodinated apoptosisâ€“inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies. British Journal of Pharmacology, 2012, 165, 2203-2212.	2.7	16
59	Value of automatic patient motion detection and correction in myocardial perfusion imaging using a CZT-based SPECT camera. Journal of Nuclear Cardiology, 2018, 25, 419-428.	1.4	16
60	Utility of an intraoperative gamma probe in the surgical management of secondary or tertiary hyperparathyroidism. American Journal of Surgery, 2008, 196, 13-18.	0.9	15
61	Evaluation of99mTc-MAMA-chrysamine G as anin vivoprobe for amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2001, 8, 202-214.	1.4	14
62	Detection of bone metastases in thyroid cancer patients: Bone scintigraphy or 18F-FDG PET?. Nuclear Medicine Communications, 2007, 28, 597-602.	0.5	14
63	Myocardial perfusion imaging in stable symptomatic patients with extensive coronary atherosclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 136-143.	3.3	12
64	Diagnostic implications of a small-voxel reconstruction for loco-regional lymph node characterization in breast cancer patients using FDG-PET/CT. EJNMMI Research, 2018, 8, 3.	1.1	12
65	A Sensitive Tg Assay or rhTSH Stimulated Tg: What's the Best in the Long-Term Follow-Up of Patients with Differentiated Thyroid Carcinoma?. PLoS ONE, 2007, 2, e816.	1.1	11
66	Immediate dynamic lymphoscintigraphy delivers no additional value to lymphoscintigraphy 3 hr after tracer injection in sentinel lymph node biopsy in breast cancer patients. Journal of Surgical Oncology, 2007, 95, 469-475.	0.8	10
67	Comparison of 11C-methionine PET and 18F-fluorodeoxyglucose PET in differentiated thyroid cancer. Nuclear Medicine Communications, 2008, 29, 711-716.	0.5	10
68	Influence of proton-pump inhibitors on stomach wall uptake of 99mTc-tetrofosmin in cadmiumâ€“zincâ€“telluride SPECT myocardial perfusion imaging. Nuclear Medicine Communications, 2015, 36, 143-147.	0.5	10
69	Current generation time-of-flight 18F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands. Annals of Nuclear Medicine, 2016, 30, 145-152.	1.2	10
70	Diagnostic Iâ€“131 scintigraphy in patients with differentiated thyroid cancer: No additional value of higher scan dose. Annals of Nuclear Medicine, 2004, 18, 641-6.	1.2	9
71	Value of 123I-Subtraction and Single-Photon Emission Computed Tomography in Addition to Planar 99mTc-MIBI Scintigraphy Before Parathyroid Surgery. Surgery Today, 2007, 37, 1033-1041.	0.7	9
72	Uptake mechanisms of L-3-[125I]iodo-alpha-methyl-tyrosine in a human small-cell lung cancer cell line: comparison with L-1-[14C]tyrosine. Nuclear Medicine Communications, 2001, 22, 87-96.	0.5	8

#	Article	IF	Citations
73	Coronary calcium score influences referral for invasive coronary angiography after normal myocardial perfusion SPECT. Journal of Nuclear Cardiology, 2019, 26, 602-612.	1.4	8
74	Sequential SPECT/CT imaging for detection of coronary artery disease in a large cohort: evaluation of the need for additional imaging and radiation exposure. Journal of Nuclear Cardiology, 2017, 24, 212-223.	1.4	7
75	Small-voxel reconstructions significantly influence SUVs in PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1751-1752.	3.3	7
76	Does fractional flow reserve overestimate severity of LAD lesions?. Journal of Nuclear Cardiology, 2020, 27, 1306-1313.	1.4	7
77	An automated synthesis module for preparation of l-3-[123I]iodo-alpha-methyl tyrosine. Applied Radiation and Isotopes, 2001, 55, 783-788.	0.7	6
78	Impact of image processing in the detection of ischaemia using CZT-SPECT/CT. Nuclear Medicine Communications, 2015, 36, 60-68.	0.5	5
79	Changes in cardiovascular medication after coronary artery calcium scanning and normal single photon emission computed tomography myocardial perfusion imaging in symptomatic patients. American Heart Journal, 2017, 186, 56-62.	1.2	5
80	Impact of Gender on the Prognostic Value of Coronary Artery Calcium in Symptomatic Patients With Normal Single-Photon Emission Computed Tomography Myocardial Perfusion. American Journal of Cardiology, 2016, 118, 1611-1615.	0.7	4
81	Anatomically and functionally relevant coronary stenoses in patients with normal single-photon emission computed tomography but persistent stable angina. European Heart Journal Cardiovascular Imaging, 2018, 19, 1327-1333.	0.5	2
82	Optimal imaging of patients with ischaemic heart failure. Nuclear Medicine Communications, 2006, 27, 317-320.	0.5	0
83	Sequential SPECT/CT imaging starting with stress SPECT in patients with left bundle branch block suspected for coronary artery disease. European Radiology, 2017, 27, 178-187.	2.3	0